溶瘤HSV疗法增加曲美替尼入脑并增强其体内抗胶质瘤敏感性
该研究探讨MEK抑制剂曲美替尼联合溶瘤HSV-1治疗脑肿瘤的机制与疗效。体外实验显示曲美替尼可减少小胶质/巨噬细胞来源TNFα分泌;小鼠药代分析显示oHSV处理后曲美替尼血脑屏障穿透增强。联合治疗激活CD8+ T细胞免疫并延长胶质瘤小鼠生存,为联合方案提供依据。
要点
- oHSV处理可增强曲美替尼的血脑屏障穿透。
- 曲美替尼减少oHSV诱导的小胶质/巨噬细胞TNFα分泌。
- 联合治疗激活CD8+ T细胞免疫并延长荷瘤小鼠生存。
核心结论
- 本研究为溶瘤HSV联合曲美替尼治疗脑肿瘤提供了依据。
研究设计与样本
- 体外将感染胶质瘤细胞与小胶质细胞或巨噬细胞共培养,加或不加曲美替尼。
- 采用ELISA、western blotting和流式细胞术评估联合治疗效应。
- 通过小鼠血浆与脑组织药代分析评估曲美替尼中枢神经系统递送。
- 使用颅内人源与鼠源胶质瘤荷瘤的免疫缺陷及免疫健全小鼠评估抗肿瘤疗效。
主要发现
- 溶瘤HSV处理可逆转曲美替尼引起的胶质瘤MAPK通路反馈再激活。
- 体内药代分析显示oHSV处理后曲美替尼血脑屏障穿透增强。
- 曲美替尼显著减少oHSV诱导的小胶质/巨噬细胞来源TNFα分泌并延长荷瘤小鼠生存。
- 联合治疗虽降低体内TNFα产生,仍激活CD8+ T细胞免疫并提高免疫健全荷瘤小鼠生存。
临床怎么用
- 提示oHSV与曲美替尼联合可作为脑肿瘤治疗的潜在策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hyperactivation of the RAS-RAF-MEK-ERK signaling pathway is exploited by glioma cells to promote their growth and evade apoptosis. MEK activation in tumor cells can increase replication of ICP34.5-deleted herpes simplex virus type 1 (HSV-1), but paradoxically its activation in tumor-associated macrophages promotes a pro-inflammatory signaling that can inhibit virus replication and propagation. Here we investigated the effect of blocking MEK signaling in conjunction with oncolytic HSV-1 (oHSV) for brain tumors. METHODS: Infected glioma cells co-cultured with microglia or macrophages treated with or without trametinib were used to test trametinib effect on macrophages/microglia. Enzyme-linked immunosorbent assay, western blotting, and flow cytometry were utilized to evaluate the effect of the combination therapy. Pharmacokinetic (PK) analysis of mouse plasma and brain tissue was used to evaluate trametinib delivery to the CNS. Intracranial human and mouse glioma-bearing immune deficient and immune competent mice were used to evaluate the antitumor efficacy. RESULT: Oncolytic HSV treatment rescued trametinib-mediated feedback reactivation of the mitogen-activated protein kinase signaling pathway in glioma. In vivo, PK analysis revealed enhanced blood-brain barrier penetration of trametinib after oHSV treatment. Treatment by trametinib, a MEK kinase inhibitor, led to a significant reduction in microglia- and macrophage-derived tumor necrosis factor alpha (TNFα) secretion in response to oHSV treatment and increased survival of glioma-bearing mice. Despite the reduced TNFα production observed in vivo, the combination treatment activated CD8+ T-cell mediated immunity and increased survival in a glioma-bearing immune-competent mouse model. CONCLUSION: This study provides a rationale for combining oHSV with trametinib for the treatment of brain tumors.
引用
- Yoo JY, Swanner J, Otani Y, et al. Oncolytic HSV therapy increases trametinib access to brain tumors and sensitizes them in vivo. Neuro Oncol. 2019. PMID: 31063549. doi:10.1093/neuonc/noz079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。